{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:58:49Z","timestamp":1768456729735,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surgical Clinics of North America"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.suc.2009.06.008","type":"journal-article","created":{"date-parts":[[2009,10,16]],"date-time":"2009-10-16T08:20:42Z","timestamp":1255681242000},"page":"1123-1137","source":"Crossref","is-referenced-by-count":36,"title":["Carcinoid Tumors"],"prefix":"10.1016","volume":"89","author":[{"given":"Janice L.","family":"Pasieka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.suc.2009.06.008_bib1","first-page":"426","article-title":"Karzinoid tumore des Dunndarms","volume":"1","author":"Oberndorfer","year":"1907","journal-title":"Frankf Z Pathol"},{"key":"10.1016\/j.suc.2009.06.008_bib2","first-page":"1020","article-title":"A case of primary carcinoma of the ileum","volume":"2","author":"Ransom","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.suc.2009.06.008_bib3","first-page":"237","article-title":"Tumeurs endocrines se l'appendice","volume":"25","author":"Gosset","year":"2009","journal-title":"Presse Med"},{"key":"10.1016\/j.suc.2009.06.008_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.bpg.2005.03.006","article-title":"Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options","volume":"19","author":"Arnold","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.suc.2009.06.008_bib5","first-page":"196","volume":"13","author":"Lembeck","year":"1958","journal-title":"Krebsarzt"},{"key":"10.1016\/j.suc.2009.06.008_bib6","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1586\/14737140.3.6.863","article-title":"Diagnosis and treatment of carcinoid tumors","volume":"3","author":"Oberg","year":"2003","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.suc.2009.06.008_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12022-007-9005-z","article-title":"Gl-NETs\u2014uniform but also diverse","volume":"18","author":"Dayal","year":"2007","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.suc.2009.06.008_bib8","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1053\/hupa.2002.129204","article-title":"Classification of low-grade neuroendocrine tumors of midgut and unknown origin","volume":"33","author":"Van Eeden","year":"2002","journal-title":"Hum Pathol"},{"key":"10.1016\/j.suc.2009.06.008_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.suc.2009.06.008_bib10","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1023\/A:1012494309486","article-title":"Impact of chromogranin A measurement in the work-up of neuroendocrine tumors","volume":"12","author":"Baudin","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.suc.2009.06.008_bib11","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1023\/A:1012490206760","article-title":"Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience","volume":"12","author":"Stivanello","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.suc.2009.06.008_bib12","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.suc.2009.06.008_bib13","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.suc.2009.06.008_bib14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bpg.2005.05.007","article-title":"Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome)","volume":"19","author":"de Herder","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.suc.2009.06.008_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.beem.2006.12.004","article-title":"Surgery on neuroendocrine tumours","volume":"21","author":"Akerstrom","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.suc.2009.06.008_bib16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0921-4410(04)22021-X","article-title":"Neuroendocrine tumours","volume":"22","author":"Granberg","year":"2005","journal-title":"Cancer Chemother Biol Response Modif"},{"key":"10.1016\/j.suc.2009.06.008_bib17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bpg.2005.02.010","article-title":"Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract","volume":"19","author":"Kloppel","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.suc.2009.06.008_bib18","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.bpg.2005.05.002","article-title":"Endocrine tumours of the stomach","volume":"19","author":"Delle Fave","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.suc.2009.06.008_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF02739873","article-title":"Smooth muscle cell abnormalities associated with gastric ECL cell carcinoids","volume":"6","author":"Bordi","year":"1995","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.suc.2009.06.008_bib20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000098007","article-title":"Well-differentiated gastric tumors\/carcinomas","volume":"84","author":"Ruszniewski","year":"2006","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.suc.2009.06.008_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejso.2007.07.202","article-title":"Carcinoid syndrome","volume":"34","author":"Bendelow","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.suc.2009.06.008_bib22","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.gassur.2004.04.010","article-title":"Current management of gastrointestinal carcinoid tumors","volume":"8","author":"Woodside","year":"2004","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.suc.2009.06.008_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archsurg.136.1.49","article-title":"Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment","volume":"136","author":"Schindl","year":"2001","journal-title":"Arch Surg"},{"key":"10.1016\/j.suc.2009.06.008_bib24","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/0016-5085(93)90266-F","article-title":"Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study","volume":"104","author":"Rindi","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.suc.2009.06.008_bib25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.surg.2008.06.008","article-title":"The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors","volume":"144","author":"Chambers","year":"2008","journal-title":"Surgery"},{"key":"10.1016\/j.suc.2009.06.008_bib26","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11936-007-0043-0","article-title":"Carcinoid heart disease","volume":"9","author":"Bernheim","year":"2007","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.suc.2009.06.008_bib27","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/CIRCULATIONAHA.107.701367","article-title":"Carcinoid heart disease","volume":"116","author":"Bhattacharyya","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.suc.2009.06.008_bib28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.amjcard.2007.08.045","article-title":"Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century","volume":"101","author":"Bhattacharyya","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.suc.2009.06.008_bib29","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.jamcollsurg.2008.06.021","article-title":"The role of imaging studies in the staging of midgut neuroendocrine tumors","volume":"207","author":"Chambers","year":"2009","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.suc.2009.06.008_bib30","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1210\/jc.2004-1938","article-title":"Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography","volume":"90","author":"Orlefors","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.suc.2009.06.008_bib31","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1210\/er.2003-0032","article-title":"Functional imaging of endocrine tumors: role of positron emission tomography","volume":"25","author":"Pacak","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.suc.2009.06.008_bib32","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.surg.2006.07.033","article-title":"Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival","volume":"140","author":"Givi","year":"2006","journal-title":"Surgery"},{"key":"10.1016\/j.suc.2009.06.008_bib33","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00268-002-6630-z","article-title":"Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases","volume":"26","author":"Hellman","year":"2002","journal-title":"World J Surg"},{"key":"10.1016\/j.suc.2009.06.008_bib34","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/01.sla.0000164073.08093.5d","article-title":"Surgical treatment of advanced-stage carcinoid tumors: lessons learned","volume":"241","author":"Boudreaux","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.suc.2009.06.008_bib35","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1072-7515(00)00222-2","article-title":"Hepatic neuroendocrine metastases: does intervention alter outcomes?","volume":"190","author":"Chamberlain","year":"2000","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.suc.2009.06.008_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.suc.2009.06.008_bib37","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s00268-008-9510-3","article-title":"Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors","volume":"32","author":"Eriksson","year":"2008","journal-title":"World J Surg"},{"key":"10.1016\/j.suc.2009.06.008_bib38","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1245\/ASO.2006.03.071","article-title":"Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors","volume":"13","author":"Osborne","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2009.06.008_bib39","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.21389","article-title":"Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival","volume":"104","author":"Gupta","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.suc.2009.06.008_bib40","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.surg.2004.06.050","article-title":"The palliative role of 131I mIBG and 111In-octreotide\u00a0in patients with metastatic progressive neuroendocrine tumors","volume":"136","author":"Pasieka","year":"2004","journal-title":"Surgery"},{"key":"10.1016\/j.suc.2009.06.008_bib41","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00268-004-7603-1","article-title":"131I mIBG in the management of metastatic midgut carcinoid tumors","volume":"28","author":"Sywak","year":"2004","journal-title":"World J Surg"},{"key":"10.1016\/j.suc.2009.06.008_bib42","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.1996.14.6.1829","article-title":"Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors","volume":"14","author":"Taal","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.suc.2009.06.008_bib43","first-page":"1","article-title":"Long-term efficacy of high-activity111 In-pentetreotide therapy in patients with disseminated neuroendocrine tumors","volume":"44","author":"Buscombe","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.suc.2009.06.008_bib44","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.surg.2006.07.030","article-title":"Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors","volume":"140","author":"Frilling","year":"2006","journal-title":"Surgery"},{"issue":"Suppl 1","key":"10.1016\/j.suc.2009.06.008_bib45","first-page":"62S","article-title":"Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs","volume":"46","author":"Kwekkeboom","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.suc.2009.06.008_bib46","first-page":"610","article-title":"Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC","volume":"43","author":"Waldherr","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1016\/j.suc.2009.06.008_bib47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1634\/theoncologist.10-2-123","article-title":"Metastatic carcinoid tumors: a clinical review","volume":"10","author":"Zuetenhorst","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.suc.2009.06.008_bib48","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"Faiss","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.suc.2009.06.008_bib49","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.1984.2.11.1255","article-title":"Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor","volume":"2","author":"Engstrom","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.suc.2009.06.008_bib50","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1002\/1097-0142(19871215)60:12<2891::AID-CNCR2820601207>3.0.CO;2-6","article-title":"A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study","volume":"60","author":"Bukowski","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.suc.2009.06.008_bib51","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1572-0241.2007.01643.x","article-title":"Medical management of pancreatic neuroendocrine tumors","volume":"103","author":"Delaunoit","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.suc.2009.06.008_bib52","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/modpathol.3800427","article-title":"Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas","volume":"18","author":"Papouchado","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.suc.2009.06.008_bib53","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bpg.2005.06.003","article-title":"Neuroendocrine tumours (carcinoids) of the appendix","volume":"19","author":"Stinner","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.suc.2009.06.008_bib54","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"N Engl J Med"}],"container-title":["Surgical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610909000802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610909000802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T05:40:44Z","timestamp":1558590044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039610909000802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0039610909000802"],"URL":"https:\/\/doi.org\/10.1016\/j.suc.2009.06.008","relation":{},"ISSN":["0039-6109"],"issn-type":[{"value":"0039-6109","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}